Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;161(4):525-32.
doi: 10.1111/bjh.12286. Epub 2013 Mar 11.

Systemic amyloidosis in England: an epidemiological study

Affiliations
Free PMC article

Systemic amyloidosis in England: an epidemiological study

Jennifer H Pinney et al. Br J Haematol. 2013 May.
Free PMC article

Abstract

Epidemiological studies of systemic amyloidosis are scarce and the burden of disease in England has not previously been estimated. In 1999, the National Health Service commissioned the National Amyloidosis Centre (NAC) to provide a national clinical service for all patients with amyloidosis. Data for all individuals referred to the NAC is held on a comprehensive central database, and these were compared with English death certificate data for amyloidosis from 2000 to 2008, obtained from the Office of National Statistics. Amyloidosis was stated on death certificates of 2543 individuals, representing 0·58/1000 recorded deaths. During the same period, 1143 amyloidosis patients followed at the NAC died, 903 (79%) of whom had amyloidosis recorded on their death certificates. The estimated minimum incidence of systemic amyloidosis in the English population in 2008, based on new referrals to the NAC, was 0·4/100 000 population. The incidence peaked at age 60-79 years. Systemic AL amyloidosis was the most common type with an estimated minimum incidence of 0·3/100 000 population. Although there are various limitations to this study, the available data suggest the incidence of systemic amyloidosis in England exceeds 0·8/100 000 of the population.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Position of amyloidosis on death certificates among patients who attended the National Amyloidosis Centre.
Fig. 2
Fig. 2
Proportion of death certificates from England on which amyloidosis was included as a cause of death.
Fig. 3
Fig. 3
Apparent incidence of amyloidosis in 2008 stratified by Strategic Health Authority, derived solely from new referrals to the National Amyloidosis Centre (NAC). The incidence appears to fall as distance from the NAC increases (R2 = 0·64, P = 0·005).

References

    1. Cotch MF, Hoffman GS, Yerg DE, Kaufman GI, Targonski P. Kaslow RA. The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis and Rheumatism. 1996;39:87–92. - PubMed
    1. Gillmore JD, Stangou AJ, Lachmann HJ, Goodman HJ, Wechalekar AD, Acheson J, Tennent GA, Bybee A, Gilbertson J, Rowczenio D, O'Grady J, Heaton ND, Pepys MB. Hawkins PN. Organ transplantation in hereditary apolipoprotein AI amyloidosis. American Journal of Transplantation. 2006;6:2342–2347. - PubMed
    1. Gillmore JD, Lachmann HJ, Rowczenio D, Gilbertson JA, Zeng CH, Liu ZH, Li LS, Wechalekar A. Hawkins PN. Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. Journal of the American Society of Nephrology. 2009;20:444–451. - PMC - PubMed
    1. Imaizumi Y. Mortality rate of amyloidosis in Japan: secular trends and geographical variations. American Journal of Medical Genetics. 1989;34:562–568. - PubMed
    1. Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Pamboukas C, Boletis I, Marinaki S, Apostolou T, Nikitas N, Gkortzolidis G, Michalis E, Delimpasi S. Dimopoulos MA. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood. 2012;119:5384–5390. - PubMed

Publication types